** Drug developer Akero Therapeutics' AKRO.O shares rise ~2.5% to $28.78
** Citi initiates coverage of AKRO with "buy" rating
** Brokerage says AKRO is developing efruxifermin, a novel FGF21 agonist, for treating metabolic dysfunction-associated steatohepatitis (MASH)
** MASH causes an excessive accumulation of fat in the liver
** "Efruxifermin is well-positioned to differentiate in this difficult-to-treat population given its potential best-in-disease efficacy," says Citi
** Brokerage sets PT at $65, a ~131.4% upside on stock's last close
** Ten of 11 brokerages rate the stock "buy" or higher, 1 "hold"; their median PT is $46 - LSEG data
** Including session's moves, stock up ~22.23% YTD
(Reporting by Prakhar Srivastava in Bengaluru)
((Prakhar.srivastava2@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。